Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998640 | 0.81 | SMN1; SMN2 (0.71) | SMN1; SMN2ALDH1A1KDM4ENPC1TDP1 | |
| SCHEMBL999454 | 0.79 | ALDH1A1 (0.66) | SMN1; SMN2ALDH1A1TDP1MAPTMAPK1 | |
| SCHEMBL1000208 | 0.77 | RAB9A (0.66) | SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL1000093 | 0.76 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1TDP1MAPTMAPK1 | |
| SCHEMBL998689 | 0.74 | RAB9A (0.46) | SMN1; SMN2ALDH1A1NPC1TDP1RAB9A | |
| SCHEMBL2606477 | 0.73 | CNR1 (0.47) | SMN1; SMN2ALDH1A1KDM4ENPC1TDP1 | |
| SCHEMBL998360 | 0.73 | RAB9A (0.43) | SMN1; SMN2ALDH1A1NPC1TDP1RAB9A | |
| SCHEMBL999556 | 0.72 | RAB9A (0.42) | SMN1; SMN2ALDH1A1NPC1TDP1RAB9A | |
| SCHEMBL998886 | 0.72 | RAB9A (0.42) | SMN1; SMN2ALDH1A1KDM4ENPC1TDP1 | |
| SCHEMBL999393 | 0.72 | TSHR (0.46) | SMN1; SMN2RAB9ATSHRGRM5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582769-B2 | Dicycloalkyl urea glucokinase activators | NOVO NORDISK A/S (DK) | 2009-09-01 | — | — | US | disclosed |
| US-20090118501-A1 | Dicycloalkyl Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-05-07 | — | — | US | disclosed |
| EP-1904466-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006760-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118501-A1 | Dicycloalkyl Urea Glucokinase Activators | GCK, GCKR, UCK2 | SMN1; SMN2 4814/4885ALDH1A1 3782/4885KDM4E 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.